Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Investor Presentation (March 2023)

60 slides from Observe Medical ASA's investor presentation, March 2023

  1. Slide 1: Observe Medical Company presentation March 2023

    oYeovserve medical Observe Medical Company presentation March 2023

  2. Slide 2: Copyright and disclaimer

    OBSERVE MEDICAL Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be repr

  3. Slide 3: Introduction

    INTRODUCTION

  4. Slide 4: Key investment highlights

    INTRODUCTION Key investment highlights Powerful • Observe Medical has a powerful medtech commercialization platform 1 platform • Commercializing proprietary innovative products to capitalize on significant market opportunities • Unometer acquisition accelerates commercial roll-out of OM’s combined p

  5. Slide 5: Observe Medical is a Nordic medtech company with global reach

    INTRODUCTION Observe Medical is a Nordic medtech company with global reach Observe Medical in brief Current products and offerings • Commercializing proprietary innovative medtech Nordic distribution products on a global market • International distributor and partner network as well as Nordic direct

  6. Slide 6: Summary of proposed acquisitions

    INTRODUCTION Summary of proposed acquisitions 1 Market leading urine measurement portfolio 2 Production facility with strong track-record Unometer portfolio Ferrari L. facility • Opportunity to acquire • Opportunity to acquire market leading urine operative production measurement products facility f

  7. Slide 7: The new strengthened medtech platform and extended distribution network

    INTRODUCTION The new strengthened medtech platform and extended distribution network will accelerate commercialization of existing products PLATFORM • Commercializing proprietary innovative medtech products on a global market • International distributor and partner network and Nordic direct sales op

  8. Slide 8: Pathway to run-rate revenue of NOK +250 million end 2023

    INTRODUCTION Pathway to run-rate revenue of NOK +250 million end 2023 Monthly revenue development per product 2023 (NOKm) Annual run-rate NOK +250m Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Sippi Unometer Biim ultrasound probe Nordic distribution portfolio Ferrari L. portfolio Abdo Pressure Ru

  9. Slide 9: Gross margin and EBITDA

    INTRODUCTION Gross margin and EBITDA Gross margin per product 2023 (NOKm) 80% 60% 40% 20% 0% Sippi Biim Nordic Ferrari Abdo-Pressure Unometer EBITDA and EBITDA margin1 (NOKm) 300 255 40% 200 176 151 106 20% 82 100 52 34 0% 0 2023 -24 Run-rate end 2023 2024 2025 -100 -20% Total gross result EBITDA EB

  10. Slide 10: Business plan to reach positive free cash flow in 2024

    INTRODUCTION Business plan to reach positive free cash flow in the beginning of 2024 Illustrative free cash-flow forecast1 Illustrative sources & uses until year-end 2023 Sources: NOKm (approx.) Cash balance per end-of-year 2022 14 Bank loans in Norway & Italy 20-30 Funding H1 2023 30-50 Equity issu

  11. Slide 11: Acquisition rationale

    ACQUISITION RATIONALE

  12. Slide 12: Key acquisition highlights

    ACQUISITION RATIONALE Key acquisition highlights 1 4 Market leading Value chain control products and brand Production facility with optimal location in Verona, a Becomes Europe #1 urine Central European medtech measurement provider, cluster, allowing greater supporting adoption of new value-chain co

  13. Slide 13: The Unometer Portfolio

    1 ACQUISITION RATIONALE The Unometer Portfolio • Observe Medical is given the opportunity Unometer Safeti Plus is a closed urine drainage system, to acquire the urine measurement equipped with non-return valve and needleless sample port, portfolio from Convatec, consisting of Unometer™ used in opera

  14. Slide 14: Strong platform expected to strengthen sales of both Sippi and Unometer

    1 ACQUISITION RATIONALE Strong platform expected to strengthen sales of both Sippi® and Unometer Targeting global market potential Accelerates rollout of Sippi® Unometer’s market position NOK 4bn Market potential Strong market position with approx. 80- The acquisition of the Unometer Market trends a

  15. Slide 15: Extending distribution network through 600+ sales channels

    2 ACQUISITION RATIONALE Extending distribution network and market insights through more than 600 sales channels across over 50 countries Current Biim or Sippi New from Unometer • Strong distribution network enables Unometer and Sippi sales through more than 600 sales channels in 50+ new countries, a

  16. Slide 16: Intake of significant revenues and strong margins with untapped potential

    3 ACQUISITION RATIONALE Intake of significant revenues and strong margins with untapped potential Unometer portfolio historical revenues (NOKm) Gross profit 33% 30% 28% 30% • The Unometer portfolio has previously margin (%) relatively low margins as Convatec has discounted the Unometer portfolio to

  17. Slide 17: Production facility with optimal location in the heart of Europe

    4 ACQUISITION RATIONALE Production facility with optimal location in the heart of Europe Ferrari L. introduction Located in an Italian medtech cluster • Ferrari L. is a manufacturer active in the production and supply of single-use medical devices Ferrari L. • A reputable name in the industry, with

  18. Slide 18: Observe Medical controls larger part of value chain with Ferrari L.

    4 ACQUISITION RATIONALE Observe Medical controls larger part of value chain with Ferrari L. Addressed by proposed Ferrari L. acquisition Addressed by Observe Medical today Outsourced 1 2 3 4 5 6 7 Material sourcing Manufacturing Sterilization, packaging Sales and distribution Shipment & supply Custo

  19. Slide 19: Major reduction in cost of goods sold

    5 ACQUISITION RATIONALE Major reduction in cost of goods sold for both existing and new products Expected COGS reductions from • Acquiring Ferrari L. will allow OM to proposed transaction centralize it’s production, including both the Unometer portfolio and existing products ~40% reduction • In-hous

  20. Slide 20: Untapped capacity beyond current production scope

    6 ACQUISITION RATIONALE Untapped capacity beyond current production scope • OM aims to utilize the facility for its current product portfolio, along with production of the proposed acquired Unometer portfolio • Any potential remaining capacity can be utilized for production of third-party brands. Th

  21. Slide 21: Sippi

    SIPPI®

  22. Slide 22: Sippi is a unique digital and automated urine meter

    Sippi® is a unique digital and automated urine meter Sippi® is the first automated digital urine meter with biofilm control and wireless connectivity, initially sold to ICUs and wards Current generation of Sippi®, with wireless connectivity to patient data monitoring systems CE-marked and with propr

  23. Slide 23: Sippi eliminates one of the last manual monitoring procedures in the ICU

    Sippi® eliminates one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient we

  24. Slide 24: Significant market potential for Sippi with strong volume growth

    Significant market potential for Sippi® with strong volume growth Current global market potential Further potential for optimizing hospital implementation Current focus: ~400k ~0.5M Hospital ICU beds Sippi® base units Thoracic dept. 1 surgery 8 beds: 24M +30M BU1: 10 Hospital admitted to ICU p.a. Si

  25. Slide 25: Biim

    oeovserve medical

  26. Slide 26: Biim – Wireless ultrasound device

    Biim – Wireless ultrasound device Biim’s wireless pocketable ultrasound device allow for the ability to scan patients and review images in seconds Biim makes ultrasound technology available where it has not been before, and improves patient welfare, health economics and data accuracy Biim offers nur

  27. Slide 27: Biim's unique ultrasound probe stands out among competitors

    Biim’s unique ultrasound probe stands out among competitors Biim delivers a unique device… … which clearly stands out among its competitors Ultrasound made-simple Competitor concept disadvantages: Higher level of complexity adding An intuitive and low Wireless performance challenges complexity devic

  28. Slide 28: Extensive R&D since 2014 – agreement with Fresenius a major milestone

    Extensive R&D conducted since 2014 – agreement with Fresenius a major important milestone 260x Full Fresenius US rollout Phase 1 delivery Full Fresenius Completed delivery Medical Care US Pilot study phase 1 of 260 rollout would ultrasound probes correspond to 1.1m Pilot study involving Signed LOI t

  29. Slide 29: The dialysis market opens a huge potential for Biim

    The dialysis market opens for a huge potential for Biim The market potential within dialysis is huge Fresenius partnership opens extensive growth opportunities Fresenius Medical Care is the world’s leading provider of products and There are In the global market there services for people with chronic

  30. Slide 30: Untapped potential to distribute Biim in adjacent market segments

    Significant untapped potential to distribute Biim in adjacent market segments Similar medical segments …where Biim has already established partnerships Dialysis Centres Vascular Access Teams ▪ A global provider of industry-leading medical devices used to treat cancer and peripheral vascular disease

  31. Slide 31: Outlook

    OUTLOOK Ambitions and financial targets

  32. Slide 32: Revenue and gross profit targets by product

    OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Revenue and gross profit targets by product Revenue development by product Gross profit development by product (NOKm) (NOKm) 600 494 500 400 338 255 300 400 255 200 122 176 200 106 100 52 0 0 2023 Run-rate end 2023 2024 2025 2023 Run-rate end 2023 2024 2025

  33. Slide 33: Cash flow estimate based on business plan

    OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Cash flow estimate based on business plan Cash flow estimate FY 2023 Cash flow estimate FY 2024 (NOKm) (NOKm) 138-218 103-105 34-44 40-50 45-115 15-80 15-80 10-15 14 Beginning Cash Financing Investment Operating Ending Cash Beginning Cash Financing Investmen

  34. Slide 34: Outlook, priorities and next steps

    OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Outlook, priorities and next steps Multiple key milestones in the short and medium term, providing a highly attractive medtech story for shareholders Sippi and Biim Unometer and Ferrari L. Outlook Ambitions Continue to support Fresenius' Production readiness

  35. Slide 35: Appendix

    APPENDIX

  36. Slide 36: Management team

    APPENDIX Management team Rune Nystad Per Arne Nygård Carsten Bøgh Jørgen Mann Nilsen Jenny Wennerberg Chief Executive Officer Chief Financial Officer Chief Technology Officer Chief Commercial Officer QA & RA Director 20+ years of experience 20+ years of experience 20+ years experience from 20+ years

  37. Slide 37: Board of Directors

    APPENDIX Board of Directors Terje Bakken Sanna Rydberg Kathrine Gamborg Andreassen Line Tønnessen Eskild Endrerud Chairman of the Board Board Member Board Member Board Member Board Member Terje is a partner at Reiten Sanna is VD at Unilabs Kathrine is the CEO of Line is an Investment Eskild is CEO a

  38. Slide 38: Largest shareholders and company structure

    APPENDIX Largest shareholders as of 28 February 2023 Company structure Rank Name Number of shares % of top 20 % of total Country INGERØ REITEN INVESTMENT 1 COMPANY AS 9 653 680 29.24 % 18.05 % Norway 2 NAVAMEDIC ASA 4 222 727 12.79 % 7.89 % Norway Observe Medical ASA (Norway) 3 RO, LARS 3 340 000 10

  39. Slide 39: Consolidated Statement of Comprehensive Income

    UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Consolidated Statement of Comprehensive Income (Amounts in NOK thousand) Q4 2022 Q4 2021 FY 2022 FY 2021 Operating revenues 4 132 3 591 19 521 24 042 Cost of materials 5 113 2 519 14 344 14 524 Gross result -980 1 071 5 177 9 519 Employee benefit expen

  40. Slide 40: Statement of financial position (1 of 2)

    UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Statement of financial position (1 of 2)

  41. Slide 41: Statement of financial position (2 of 2)

    UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Statement of financial position (2 of 2)

  42. Slide 42: Cash flow statement

    UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Cash flow statement

  43. Slide 43: Three scientific articles support the clinical value of Sippi

    APPENDIX Three scientific articles have been published Protected by IPR supporting the clinical value of Sippi® portfolio 1) A. Eklund, M. Slettengren & Jan van der Linden (2015) Performance and user evaluation of a novel ▪ The Sippi® global patent situation is capacitance-based automatic urinometer

  44. Slide 44: Pro forma financials

    PRO FORMA FINANCIALS

  45. Slide 45: Pro forma historical revenue bridge and gross margins

    PRO FORMA FINANCIALS Pro forma historical revenue bridge and gross margins Illustrative pro forma revenue bridge FY 20221,2 Gross margin pro forma FY 2022 (NOKm) 80% 60% 40% 20% 0% Observe Medical Unometer Abdo-Pressure Ferrari L. Pro forma Sippi Biim Nordic Ferrari Abdo-Pressure Unometer Current 1

  46. Slide 46: Appendix II – Financial targets by product

    oeovserve medical APPENDIX Il Financial targets by product

  47. Slide 47: Financial targets - Unometer

    FINANCIAL TARGET PER PRODUCT Financial targets - Unometer Unometer - Revenue and gross margin (NOKm) 33% 43% 43% 400 314 300 197 200 134 84 100 50 16 0 2023 2024 2025 Revenue Gross result Gross margin Unometer – Sales volume (#units) Volume targets 4 139 761 4 199 953 3 921 344 3 967 235 4 000 000 2

  48. Slide 48: Financial targets – Abdo Pressure

    FINANCIAL TARGET PER PRODUCT Financial targets – Abdo Pressure Abdo Pressure - Revenue and gross margin (NOKm) 70% 87% 87% 30 23 20 20 17 20 10 4 3 0 2023 2024 2025 Revenue Gross result Gross margin Abdo Pressure – Sales volume (#units) Volume targets 84 015 63 210 65 000 63 295 55 000 56 843 12 000

  49. Slide 49: Financial targets – Sippi

    FINANCIAL TARGET PER PRODUCT Financial targets – Sippi® Accelerates rollout of Sippi® Sippi® - Revenue and gross margin Unometer’s market position (NOKm) 65% 81% 85% 78% 88% 88% 22.9 19.8 6.3 5.4 0.8 0.6 Strong market position with The acquisition of the Unometer approx. 80-90% market share in portf

  50. Slide 50: Financial targets – Biim

    FINANCIAL TARGET PER PRODUCT Financial targets – Biim Fresenius partnership opens extensive Biim - Revenue and gross margin (NOKm) growth opportunities 58% 76% 76% Fresenius Medical Care is a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion an

  51. Slide 51: Financial targets – Nordic

    FINANCIAL TARGET PER PRODUCT Financial targets – Nordic Nordic distribution portfolio consisting of Nordic - Revenue and gross margin (NOKm) medtech devices and disposables 33% 35% 36% 27 24 20 10 8 7 2023 2024 2025 Revenue Gross result Gross margin 51

  52. Slide 52: Financial targets – Ferrari L.

    FINANCIAL TARGET PER PRODUCT Financial targets – Ferrari L. Ferrari L. - Revenue and gross margin (NOKm) 45% 49% 49% 49% 50% 50% 40 Financial targets 35 35 33 30 30 27 25 25 25 20 18 17 14 15 15 13 12 10 5 - 2020 2021 2022* 2023** 2024 2025 Revenue Gross result Gross margin *Ferrari L. guiding EUR 3

  53. Slide 53: Financial targets - details

    FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Sippi base unit Volum 50 600 1 800 10 120 Sippi base unit Price 6 000 6 000 6 000 6 000 6 000 Sippi base unit Cogs 1 300 700 700 1 300 1 300 Sippi base uni

  54. Slide 54: Financial targets - details

    FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Unometer Safeti + Volum 150 000 1 800 000 2 700 000 70 000 840 000 Unometer Safeti + Price 80 80 80 80 80 Unometer Safeti + Cogs 55 45 45 55 55 Unometer Sa

  55. Slide 55: Financial targets - details

    FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Abdo-Pressure stand alone Volum 9 000 30 000 35 000 1 300 15 600 Abdo-Pressure stand alone Price 340 340 340 340 340 Abdo-Pressure stand alone Cogs 98 30 3

  56. Slide 56: Financial targets - details

    FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Biim Ultrasound probe Volum 500 1 300 1 600 100 1 200 Biim Ultrasound probe Price 45 000 45 000 45 000 45 000 45 000 Biim Ultrasound probe Cogs 19 000 11 0

  57. Slide 57: Appendix III – Unometer historical sales volume by country

    APPENDIX III Unometer - Historical sales volume by country

  58. Slide 58: Unometer Safeti Plus - Historical sales volume by country

    Unometer Safeti Plus - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 Germany 719 440 781 200 636 640 671 000 Italy 325 300 331 356 456 300 296 721 United Kingdom 153 360 84 460 74 490 130 520 Denmark 109 294 136 322 109 510 127 069 Australia 86 550 115 740 106 270 96 1

  59. Slide 59: Unometer 500 - Historical sales volume by country

    Unometer 500 - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 United Kingdom 940 143 978 723 749 141 873 152 Spain 227 766 249 711 294 294 232 643 Denmark 73 416 73 472 76 160 77 411 Austria 40 110 32 340 33 992 44 725 Netherlands 63 770 45 108 34 748 45 995 Belgium 47

  60. Slide 60: Abdo Pressure - Historical sales volume by country

    Abdo Pressure - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 Spain 13 530 14 460 14 700 16 573 Poland 6 000 4 200 7 990 18 540 Italy 6 470 8 130 8 930 10 107 Germany 7 560 10 440 7 850 8 960 France 5 740 5 920 4 960 8 827 United Kingdom 3 186 3 470 3 860 4 427 Austria

Observe Medical — Investor Presentation (March 2023) on 6ix